Trial Profile
NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cyclophosphamide; Topotecan
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms N2013-02
- 07 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 07 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Jan 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.